Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Research & Development (2021 - 2023)

Acro Biomedical (ACBM) has 3 years of Research & Development data on record, last reported at $396550.0 in Q3 2023.

  • For Q3 2023, Research & Development fell 84.26% year-over-year to $396550.0; the TTM value through Jun 2024 reached $396550.0, down 95.8%, while the annual FY2023 figure was $4.8 million, 52.43% down from the prior year.
  • Research & Development reached $396550.0 in Q3 2023 per ACBM's latest filing, down from $1.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $2.5 million in Q4 2021 and bottomed at $396550.0 in Q3 2023.
  • Average Research & Development over 3 years is $2.0 million, with a median of $2.5 million recorded in 2021.
  • Peak YoY movement for Research & Development: surged 292.69% in 2022, then crashed 84.26% in 2023.
  • A 3-year view of Research & Development shows it stood at $2.5 million in 2021, then changed by 0.0% to $2.5 million in 2022, then plummeted by 84.26% to $396550.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Research & Development were $396550.0 in Q3 2023, $1.9 million in Q2 2023, and $2.5 million in Q1 2023.